Literature DB >> 9892326

Current strategies for management of hypertensive renal disease.

M A Moore1, M Epstein, L Agodoa, L D Dworkin.   

Abstract

The incidence of hypertensive end-stage renal disease continues to increase annually. To reduce this incidence, it is necessary to control systolic and diastolic hypertension. Reversible causes should always be sought in any hypertensive patient who develops renal insufficiency. Blood pressure should be reduced to 130/85 mm Hg, and in African Americans with hypertensive renal failure, reducing the blood pressure to 120/75 mm Hg may be beneficial. Any antihypertensive treatment regimen that effectively lowers blood pressure will help slow progressive renal failure. Whenever possible, an angiotensin-converting enzyme inhibitor should be part of the treatment, since these drugs have been shown to be renoprotective beyond their antihypertensive effect in certain renal disease categories.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892326     DOI: 10.1001/archinte.159.1.23

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

1.  African American hypertensive nephropathy maps to a new locus on chromosome 9q31-q32.

Authors:  Ki Wha Chung; Robert E Ferrell; Demetrius Ellis; Michael Barmada; Michael Moritz; David N Finegold; Ronald Jaffe; Abhay Vats
Journal:  Am J Hum Genet       Date:  2003-07-01       Impact factor: 11.025

Review 2.  Managing chronic renal insufficiency--intertwined roles of non-nephrologist and nephrologist.

Authors:  Onyekachi Ifudu; Eli A Friedman
Journal:  J Natl Med Assoc       Date:  2003-01       Impact factor: 1.798

3.  Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient.

Authors:  M A Moore
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jan-Feb       Impact factor: 3.738

Review 4.  Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension.

Authors:  Michael A Moore
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.